Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Bladder Cancer, June 2017

Free Subscription


Abstracts

Retrieve all available abstracts of the following 126 articles:
HTML format


 

Single Articles

  1. TAN M, Zhang D, Zhang E, Xu D, et al
    SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF-betaRI.
    Mol Carcinog. 2017 Jun 2. doi: 10.1002/mc.22687.
    Abstract    

    Abstract available

  2. AYATI M, Nowroozi MR, Mortazavi A, Ohadian Moghadam S, et al
    Management of Hepatic Granulomatous Tuberculosis After BCG Therapy for Bladder Cancer.
    Urol Case Rep. 2017;13:158-159.
    Abstract    

    Abstract available

  3. ARAGON-CHING JB, Pagliaro LC
    New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis.
    Am Soc Clin Oncol Educ Book. 2017;37:330-336.
    Abstract    

    Abstract available

  4. SATO A, Asano T, Okubo K, Isono M, et al
    Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically By Inducing Endoplasmic Reticulum Stress.
    Oncol Res. 2017 May 26. doi: 10.3727/096504017X14957929842972.
    Abstract    

    Abstract available

  5. KIM JK, Jeong CW, Kwak C, Kim HH, et al
    Progression to T1 High Grade (T1HG) from a Lower Stage/Grade is Associated with Poorer Survival Outcomes than Initial Diagnosis with T1HG Bladder Cancer.
    Ann Surg Oncol. 2017 May 30. doi: 10.1245/s10434-017-5902.
    Abstract    

    Abstract available

  6. XIE X, Rui W, He W, Shao Y, et al
    Discoidin domain receptor 1 activity drives an aggressive phenotype in bladder cancer.
    Am J Transl Res. 2017;9:2500-2507.
    Abstract    

    Abstract available

  7. MULLARD A
    Immuno-oncology upset in bladder cancer.
    Nat Rev Drug Discov. 2017;16:375.
    Abstract    



  8. CUMBERBATCH K, He T, Thorogood Z, Gartrell BA, et al
    Emerging Drugs for Urothelial (Bladder) Cancer.
    Expert Opin Emerg Drugs. 2017 May 30. doi: 10.1080/14728214.2017.1336536.
    Abstract    

    Abstract available

  9. NICOLAZZO C, Busetto GM, Del Giudice F, Sperduti I, et al
    The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC).
    J Cancer Res Clin Oncol. 2017 May 29. doi: 10.1007/s00432-017-2449.
    Abstract    

    Abstract available

  10. WANG Y, Kang XL, Zeng FC, Xu CJ, et al
    Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer.
    Pathol Res Pract. 2017 Apr 20. pii: S0344-0338(16)30606.
    Abstract    

    Abstract available

  11. YU D, Zhang C, Gui J
    RNA-binding protein HuR promotes bladder cancer progression by competitively binding to the long noncoding HOTAIR with miR-1.
    Onco Targets Ther. 2017;10:2609-2619.
    Abstract    

    Abstract available

  12. LIN JF, Lin YC, Tsai TF, Chen HE, et al
    Cisplatin induces protective autophagy through activation of BECN1 in human bladder cancer cells.
    Drug Des Devel Ther. 2017;11:1517-1533.
    Abstract    

    Abstract available

  13. WU Z, Wang S, Jiang F, Li Q, et al
    Mass spectrometric detection combined with bioinformatic analysis identified possible protein markers and key pathways associated with bladder cancer.
    Gene. 2017 May 25. pii: S0378-1119(17)30411-0. doi: 10.1016/j.gene.2017.
    Abstract    

    Abstract available

  14. VETTERLEIN MW, Meyer CP, Leyh-Bannurah SR, Mayr R, et al
    Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort.
    Clin Genitourin Cancer. 2017 Apr 26. pii: S1558-7673(17)30105.
    Abstract    

    Abstract available

  15. LIANG Z, Wang X, Xu X, Xie B, et al
    MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway.
    Mol Cancer. 2017;16:96.
    Abstract    

    Abstract available

  16. MALVIYA K, Fernandes G, Naik L, Kothari K, et al
    Utility of the Paris System in Reporting Urine Cytology.
    Acta Cytol. 2017;61:145-152.
    Abstract    

    Abstract available

  17. PAGLIARULO V, Alba S, Gallone MF, Di Stasi S, et al
    Diagnostic Accuracy of Hexaminolevulinate in a Cohort of Patients Undergoing Radical Cystectomy.
    J Endourol. 2017;31:405-411.
    Abstract    

    Abstract available

  18. XU X, Zhang X, Tian Q, Zhang G, et al
    Three-dimensional texture features from intensity and high-order derivative maps for the discrimination between bladder tumors and wall tissues via MRI.
    Int J Comput Assist Radiol Surg. 2017;12:645-656.
    Abstract    

    Abstract available

  19. LADURNER C, Comploj E, Trenti E, Palermo S, et al
    Radical cystectomy: do we need standardization?
    Expert Rev Anticancer Ther. 2017;17:101-107.
    Abstract    

    Abstract available

  20. ZHANG H, Guo Y, Song Y, Shang C, et al
    Long noncoding RNA GAS5 inhibits malignant proliferation and chemotherapy resistance to doxorubicin in bladder transitional cell carcinoma.
    Cancer Chemother Pharmacol. 2017;79:49-55.
    Abstract    

    Abstract available

  21. DENG T, Liu B, Duan X, Zhang T, et al
    Systematic Review and Cumulative Analysis of the Combination of Mitomycin C plus Bacillus Calmette-Guerin (BCG) for Non-Muscle-Invasive Bladder Cancer.
    Sci Rep. 2017;7:3172.
    Abstract    

    Abstract available

  22. PEI N, Mao Y, Wan P, Chen X, et al
    Angiotensin II type 2 receptor promotes apoptosis and inhibits angiogenesis in bladder cancer.
    J Exp Clin Cancer Res. 2017;36:77.
    Abstract    

    Abstract available

  23. LIU ZH, Zheng FF, Mao YL, Ye LF, et al
    Effects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer.
    Oncol Lett. 2017;13:4818-4824.
    Abstract    

    Abstract available

  24. KIM CJ, Tambe Y, Mukaisho KI, Sugihara H, et al
    Periostin suppresses in vivo invasiveness via PDK1/Akt/mTOR signaling pathway in a mouse orthotopic model of bladder cancer.
    Oncol Lett. 2017;13:4276-4284.
    Abstract    

    Abstract available

  25. LIU S, Liang B, Jia H, Jiao Y, et al
    Evaluation of cell death pathways initiated by antitumor drugs melatonin and valproic acid in bladder cancer cells.
    FEBS Open Bio. 2017;7:798-810.
    Abstract    

    Abstract available

  26. RAMMANT E, Bultijnck R, Sundahl N, Ost P, et al
    Rehabilitation interventions to improve patient-reported outcomes and physical fitness in survivors of muscle invasive bladder cancer: a systematic review protocol.
    BMJ Open. 2017;7:e016054.
    Abstract    

    Abstract available

  27. GU W, Lin Y, Gou X, He W, et al
    Tea Polyphenol inhibits autophagy to sensitize Epirubicin-induced apoptosis in human bladder cancer cells.
    Neoplasma. 2017 Jun 8. doi: 10.4149/neo_2017.
    Abstract    

    Abstract available

  28. WANG M, Teng XD
    [Research progress in molecular classification of muscle invasive bladder cancer].
    Zhonghua Bing Li Xue Za Zhi. 2017;46:439-442.
    Abstract    



  29. HUANG Y, Fang C, Shi JW, Wen Y, et al
    Identification of hMex-3A and its effect on human bladder cancer cell proliferation.
    Oncotarget. 2017 May 22. doi: 10.18632/oncotarget.18050.
    Abstract    

    Abstract available

  30. WANG XC, Wang J, Tao HH, Zhang C, et al
    Combined effects of NQO1 Pro187Ser or SULT1A1 Arg213His polymorphism and smoking on bladder cancer risk: Two meta-analyses.
    Int J Occup Med Environ Health. 2017 Jun 7. pii: 65296.
    Abstract    

    Abstract available

  31. SHIVAKUMAR M, Lee Y, Bang L, Garg T, et al
    Identification of epigenetic interactions between miRNA and DNA methylation associated with gene expression as potential prognostic markers in bladder cancer.
    BMC Med Genomics. 2017;10.
    Abstract    

    Abstract available

  32. SUZUKI K, Hanashima F, Shirotake S, Kodaira K, et al
    Determining the optimum way to maintain quality of life for very elderly patients with advanced bladder cancer and poor performance status: A case report.
    Mol Clin Oncol. 2017;6:968-970.
    Abstract    

    Abstract available

  33. LI S, Zhang Y, Liu Q, Zhao Q, et al
    Oxymatrine inhibits proliferation of human bladder cancer T24 cells by inducing apoptosis and cell cycle arrest.
    Oncol Lett. 2017;13:4453-4458.
    Abstract    

    Abstract available

  34. KATES M, Nirschl T, Sopko NA, Matsui H, et al
    Intravesical BCG induces CD4+ T-Cell Expansion in an Immune Competent Model of Bladder Cancer.
    Cancer Immunol Res. 2017 Jun 6. pii: canimm.0267.2016.
    Abstract    

    Abstract available

  35. SCHULZ GB, Grimm T, Buchner A, Jokisch F, et al
    Prognostic Value of the Preoperative Platelet-to-leukocyte Ratio for Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer.
    Clin Genitourin Cancer. 2017 May 10. pii: S1558-7673(17)30133.
    Abstract    

    Abstract available

  36. HAFEEZ S, McDonald F, Lalondrelle S, McNair H, et al
    Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment.
    Int J Radiat Oncol Biol Phys. 2017;98:115-122.
    Abstract    

    Abstract available

  37. LOPEZ JI, Angulo JC, Martin A, Sanchez-Chapado M, et al
    A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.
    APMIS. 2017 Jun 6. doi: 10.1111/apm.12719.
    Abstract    

    Abstract available

  38. HE H, Chang R, Zhang T, Yang C, et al
    ATM mediates DAB2IP-deficient bladder cancer cell resistance to ionizing radiation through the p38MAPK and NF-kappaB signaling pathway.
    Mol Med Rep. 2017 Jun 6. doi: 10.3892/mmr.2017.6689.
    Abstract    

    Abstract available

  39. SHEN M, Zhou L, Zhou P, Zhou W, et al
    Lymphotoxin beta receptor activation promotes mRNA expression of RelA and pro-inflammatory cytokines TNFalpha and IL-1beta in bladder cancer cells.
    Mol Med Rep. 2017 Jun 1. doi: 10.3892/mmr.2017.6676.
    Abstract    

    Abstract available

  40. WEINHAUS B, Guin S
    Involvement of glycogen debranching enzyme in bladder cancer.
    Biomed Rep. 2017;6:595-598.
    Abstract    

    Abstract available

  41. CHOE J, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, et al
    Updates for the radiologist in non-muscle-invasive, muscle-invasive, and metastatic bladder cancer.
    Abdom Radiol (NY). 2017 Jun 3. doi: 10.1007/s00261-017-1195.
    Abstract    

    Abstract available

  42. SHAO Y, Zhu W, Da J, Xu M, et al
    Bisdemethoxycurcumin in combination with alpha-PD-L1 antibody boosts immune response against bladder cancer.
    Onco Targets Ther. 2017;10:2675-2683.
    Abstract    

    Abstract available

  43. MEARINI E, Poli G, Cochetti G, Boni A, et al
    Expression of urinary miRNAs targeting NLRs inflammasomes in bladder cancer.
    Onco Targets Ther. 2017;10:2665-2673.
    Abstract    

    Abstract available

  44. MOKHTAR A, Al MM, Al WM, Othman KA, et al
    Is survival after radical cystectomy for bladder cancer in Saudi patients different from that of Western patients?
    Ann Saudi Med. 2017;37:194-200.
    Abstract    

    Abstract available

  45. DA SILVA GN, Filoni LT, Salvadori MC, Salvadori DMF, et al
    Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
    Pathol Oncol Res. 2017 Jun 2. doi: 10.1007/s12253-017-0255.
    Abstract    

    Abstract available

  46. BLASZKEWICZ M
    Highlight report: N-acetyltransferase 2 and urinary bladder cancer risk.
    Arch Toxicol. 2017 Jun 2. doi: 10.1007/s00204-017-2001.
    Abstract    



  47. APPUNNI S, Anand V, Khandelwal M, Seth A, et al
    Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder.
    Tumour Biol. 2017;39:1010428317699112.
    Abstract    

    Abstract available

  48. LHUNGAY TP, Colvin A, Warncke J, Somerset H, et al
    Seventy-Year-Old Man With Large Bladder Mass: Diagnostic and Clinical Challenges of an Uncommon Neoplasm.
    Oncology (Williston Park). 2017;31:210-2.
    Abstract    



  49. AKINGBOYE A, Schultz H, Taylor GA
    Papillary transitional cell bladder carcinoma and systematized epidermal nevus syndrome.
    Cutis. 2017;99:61-64.
    Abstract    

    Abstract available

  50. NASELLI A, Puppo P
    En Bloc Transurethral Resection of Bladder Tumors: A New Standard?
    J Endourol. 2017;31.
    Abstract    

    Abstract available

  51. BLACK PC, Sridhar S
    New research in bladder cancer, ASCO-GU 2017.
    Can Urol Assoc J. 2017;11.
    Abstract    



  52. HAMANO I, Hatakeyama S, Iwamura H, Fujita N, et al
    Preoperative chronic kidney disease predicts poor oncological outcomes after radical cystectomy in patients with muscle-invasive bladder cancer.
    Oncotarget. 2017 May 29. doi: 10.18632/oncotarget.18248.
    Abstract    

    Abstract available

  53. POLO A, Crispo A, Cerino P, Falzone L, et al
    Environment and bladder cancer: molecular analysis by interaction networks.
    Oncotarget. 2017 May 26. doi: 10.18632/oncotarget.18222.
    Abstract    

    Abstract available

  54. LIU Q, Liao B, Tian Y, Chen Y, et al
    Total fluid consumption and risk of bladder cancer: a meta-analysis with updated data.
    Oncotarget. 2017 May 23. doi: 10.18632/oncotarget.18100.
    Abstract    

    Abstract available

  55. GU W, Yin H, Liu Y, Gou X, et al
    [The mechanism underlying the effects of tea polyphenol on epirubicin-induced autophagy and apoptosis in T24 bladder cancer cells].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017;33:772-777.
    Abstract    

    Abstract available

  56. RAEISI SHAHRAKI H, Bemani P, Jalali M
    Classification of Bladder Cancer Patients via Penalized Linear Discriminant Analysis
    Asian Pac J Cancer Prev. 2017;18:1453-1457.
    Abstract    

    Abstract available

  57. MARTINI T, Wezel F, Lobig N, Mitterberger MJ, et al
    [Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guerin instillation therapy].
    Aktuelle Urol. 2017 Jun 13. doi: 10.1055/s-0043-108944.
    Abstract    

    Abstract available

  58. YASAR O, Akcay T, Obek C, Turegun FA, et al
    Significance of S100A8, S100A9 and calprotectin levels in bladder cancer.
    Scand J Clin Lab Invest. 2017 Jun 13:1-5. doi: 10.1080/00365513.2017.1336567.
    Abstract    

    Abstract available

  59. HUANG J, Schisler J, Wong HC, Rosser CJ, et al
    Intravesical ALT-803 for BCG-unresponsive Bladder Cancer - A Case Report.
    Urol Case Rep. 2017;14:15-17.
    Abstract    

    Abstract available

  60. WU CT, Lin WY, Chang YH, Chen WC, et al
    Impact of CD44 expression on radiation response for bladder cancer.
    J Cancer. 2017;8:1137-1144.
    Abstract    

    Abstract available

  61. XU Z, Li X, Qin Z, Xue J, et al
    Association of N-acetyltransferase 1 polymorphism and bladder cancer risk: an updated meta-analysis and trial sequential analysis.
    Int J Biol Markers. 2017 Jun 7:0. doi: 10.5301/ijbm.5000269.
    Abstract    

    Abstract available

  62. MERTENS LS, Horenblas S
    Related to: [18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer.
    Scand J Urol. 2017 Jun 12:1-2. doi: 10.1080/21681805.2017.1329229.
    Abstract    



  63. BOTE HE, Alaoui AE, Oussama Z, Sayegh HE, et al
    [Neuroendocrine carcinoma of the bladder: about 5 cases].
    Pan Afr Med J. 2017;26:92.
    Abstract    

    Abstract available

  64. MBETHE D, Moudouni S, Dahami Z, Lakmichi MA, et al
    [Leiomyosarcoma of the urinary bladder treated using laparoscopic cystectomy and bladder replacement by enterocystoplasty: about a case].
    Pan Afr Med J. 2017;26:26.
    Abstract    

    Abstract available

  65. KONDO M, Hotta Y, Ando R, Yasui T, et al
    The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
    Cancer Chemother Pharmacol. 2017;79:995-1001.
    Abstract    

    Abstract available

  66. BONIOL M, Koechlin A, Sorahan T, Jakobsson K, et al
    Cancer incidence in cohorts of workers in the rubber manufacturing industry first employed since 1975 in the UK and Sweden.
    Occup Environ Med. 2017;74:417-421.
    Abstract    

    Abstract available

  67. NAITO A, Taguchi S, Nakagawa T, Matsumoto A, et al
    Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder.
    World J Urol. 2017;35:97-103.
    Abstract    

    Abstract available

  68. PINEDA S, Van Steen K, Malats N
    Integrative eQTL analysis of tumor and host omics data in individuals with bladder cancer.
    Genet Epidemiol. 2017 Jun 23. doi: 10.1002/gepi.22053.
    Abstract    

    Abstract available

  69. LI T, Sun X, Jiang X
    UCA1 involved in the metformin-regulated bladder cancer cell proliferation and glycolysis.
    Tumour Biol. 2017;39:1010428317710823.
    Abstract    

    Abstract available

  70. WANG Z, Wang X, Zhang D, Yu Y, et al
    Long non-coding RNA urothelial carcinoma-associated 1 as a tumor biomarker for the diagnosis of urinary bladder cancer.
    Tumour Biol. 2017;39:1010428317709990.
    Abstract    

    Abstract available

  71. PHILLIPS RM, Hendriks HR, Sweeney JB, Reddy G, et al
    Efficacy, pharmacokinetic and pharmacodynamic evaluation of Apaziquone in the treatment of non-muscle invasive bladder cancer.
    Expert Opin Drug Metab Toxicol. 2017 Jun 21. doi: 10.1080/17425255.2017.1341490.
    Abstract    

    Abstract available

  72. ZHANG Z, Fan W, Deng Q, Tang S, et al
    The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies.
    Oncotarget. 2017 Jun 16. doi: 10.18632/oncotarget.18521.
    Abstract    

    Abstract available

  73. BEANE FREEMAN LE, Cantor KP, Baris D, Nuckols JR, et al
    Bladder Cancer and Water Disinfection By-product Exposures through Multiple Routes: A Population-Based Case-Control Study (New England, USA).
    Environ Health Perspect. 2017;125:067010.
    Abstract    

    Abstract available

  74. DUAN R, Zhang Z, Zheng F, Wang L, et al
    Combining protein and miRNA quantification for bladder cancer analysis.
    ACS Appl Mater Interfaces. 2017 Jun 21. doi: 10.1021/acsami.7b05639.
    Abstract    

    Abstract available

  75. WU JH, Deng YL, Liu Q, Yu JC, et al
    Induction of apoptosis and autophagy by calcifying nanoparticles in human bladder cancer cells.
    Tumour Biol. 2017;39:1010428317707688.
    Abstract    

    Abstract available

  76. KHETRAPAL P, Tan WS, Lamb B, Tan M, et al
    The Role of Robotics in the Invasive Management of Bladder Cancer.
    Curr Urol Rep. 2017;18:57.
    Abstract    

    Abstract available


  77. Targeting Nectin-4 in Bladder Cancer.
    Cancer Discov. 2017 Jun 20. doi: 10.1158/2159-8290.CD-NB2017.
    Abstract    

    Abstract available

  78. PETRYLAK DP
    Immunotherapy: The Wave of the Future in Bladder Cancer?
    Clin Genitourin Cancer. 2017;15.
    Abstract    

    Abstract available

  79. VOELKER R
    Immunotherapy for Bladder Cancer.
    JAMA. 2017;317:2363.
    Abstract    



  80. MERTENS LS, Horenblas S
    Bladder cancer: oligometastases and imaging.
    Nat Rev Urol. 2017 Jun 20. doi: 10.1038/nrurol.2017.
    Abstract    



  81. YUAN H, Yu S, Cui Y, Men C, et al
    Knockdown of mediator subunit Med19 suppresses bladder cancer cell proliferation and migration by downregulating Wnt/beta-catenin signalling pathway.
    J Cell Mol Med. 2017 Jun 19. doi: 10.1111/jcmm.13229.
    Abstract    

    Abstract available

  82. LIBERAL J, Carmo A, Gomes C, Cruz MT, et al
    Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells.
    Invest New Drugs. 2017 Jun 20. doi: 10.1007/s10637-017-0483.
    Abstract    

    Abstract available

  83. ZHONGBO L, U-Syn H, Ke Y, Chunli W, et al
    Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway.
    J Biomed Res. 2017 Jun 20. doi: 10.7555/JBR.31.20160160.
    Abstract    

    Abstract available

  84. SLAVYANSKAYA T, -Salnikova S, Sepiashvili R
    [CRITERIA FOR SELECTION OF TUMOR CELLS AND PROSPECTS FOR SPECIFIC IMMUNOTHERAPY FOR BLADDER CANCER].
    Georgian Med News. 2017;:26-34.
    Abstract    

    Abstract available

  85. SLAVYANSKAYA T, -Salnikova S
    [THE MAIN STAGES OF THE PREPARATION OF VIABLE TUMOR CELLS OF BLADDER CANCER: FROM ISOLATION OF THE TUMOR MATERIAL TILL CRYOPRESERVATION OF CELL LINES].
    Georgian Med News. 2017;:19-26.
    Abstract    

    Abstract available

  86. DETTLAFF K, Stawny M, Ogrodowczyk M, Jelinska A, et al
    Formulation and characterization of EGCG for the treatment of superficial bladder cancer.
    Int J Mol Med. 2017 Jun 14. doi: 10.3892/ijmm.2017.3024.
    Abstract    

    Abstract available

  87. LIN Y, Ge Y, Wang Y, Ma G, et al
    The association of rs710886 in lncRNA PCAT1 with bladder cancer risk in a Chinese population.
    Gene. 2017 Jun 13. pii: S0378-1119(17)30473-0. doi: 10.1016/j.gene.2017.
    Abstract    

    Abstract available

  88. LYNCH HN, Zu K, Kennedy EM, Lam T, et al
    Quantitative assessment of lung and bladder cancer risk and oral exposure to inorganic arsenic: Meta-regression analyses of epidemiological data.
    Environ Int. 2017 Jun 16. pii: S0160-4120(16)30336.
    Abstract    

    Abstract available

  89. SUGIURA S, Noto N, Koizumi M, Takamoto D, et al
    [Post-Operative Single Immediate Intravesical Instillation Chemotherapy as Prophylaxis for Reccurence after Transurethral Resection of Low Risk Non-Muscle-Invasive Bladder Cancer].
    Hinyokika Kiyo. 2017;63:183-187.
    Abstract    

    Abstract available

  90. ZHU J, Li Y, Tian Z, Hua X, et al
    ATG7 Overexpression Is Crucial for Tumorigenic Growth of Bladder Cancer In Vitro and In Vivo by Targeting the ETS2/miRNA196b/FOXO1/p27 Axis.
    Mol Ther Nucleic Acids. 2017;7:299-313.
    Abstract    

    Abstract available

  91. DEL BENE G, Sternberg CN
    Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future.
    Urologia. 2017 Jun 14:0. doi: 10.5301/uj.5000230.
    Abstract    

    Abstract available

  92. FILIPOVA E, Uzunova K, Kalinov K, Vekov T, et al
    Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.
    Diabetes Ther. 2017 Jun 16. doi: 10.1007/s13300-017-0273.
    Abstract    

    Abstract available

  93. ZHANG S, Zhang G, Guo H
    DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer.
    Tumour Biol. 2017;39:1010428317703822.
    Abstract    

    Abstract available

  94. RAILKAR R, Krane LS, Li QQ, Sanford T, et al
    Epidermal Growth Factor Receptor (EGFR) Targeted Photoimmunotherapy (PIT) for the Treatment of EGFR expressing Bladder Cancer.
    Mol Cancer Ther. 2017 Jun 15. pii: molcanther.0924.2016.
    Abstract    

    Abstract available

  95. WANG W, Shen F, Wang C, Lu W, et al
    MiR-1-3p inhibits the proliferation and invasion of bladder cancer cells by suppressing CCL2 expression.
    Tumour Biol. 2017;39:1010428317698383.
    Abstract    

    Abstract available

  96. DA COSTA E, Melo T, Moreira AS, Bernardo C, et al
    Valorization of Lipids from Gracilaria sp. through Lipidomics and Decoding of Antiproliferative and Anti-Inflammatory Activity.
    Mar Drugs. 2017;15.
    Abstract    

    Abstract available

  97. HIGASHINO T, Nakatsuji H, Fukuda R, Okamoto H, et al
    Hexaphyrin as a Potential Theranostic Dye for Photothermal Therapy and 19 F Magnetic Resonance Imaging.
    Chembiochem. 2017;18:951-959.
    Abstract    

    Abstract available

  98. PATEL R, Barker HE, Kyula J, McLaughlin M, et al
    An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
    Radiother Oncol. 2017 Jan 25. pii: S0167-8140(16)34478.
    Abstract    

    Abstract available

  99. DOWNES MR, Weening B, van Rhijn BW, Have CL, et al
    Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
    Histopathology. 2017;70:281-289.
    Abstract    

    Abstract available

  100. JANSSEN S, Manig L, Schild SE, Rades D, et al
    Radiotherapy of Primary or Recurrent Bladder Cancer in the Very Elderly.
    Anticancer Res. 2017;37:3287-3290.
    Abstract    

    Abstract available

  101. AFSHAR M, Goodfellow H, Jackson-Spence F, Evison F, et al
    Centralisation of radical cystectomies for bladder cancer in England, a decade on from the 'Improving Outcomes Guidance': The case for super centralisation.
    BJU Int. 2017 Jun 8. doi: 10.1111/bju.13929.
    Abstract    

    Abstract available

  102. NGO B, Papa N, Perera M, Bolton D, et al
    Predictors of delay to cystoscopy and adequacy of investigations in patients with haematuria.
    BJU Int. 2017;119 Suppl 5:19-25.
    Abstract    

    Abstract available

  103. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    Abstract    

    Abstract available

  104. MACLEOD LC, Pham KN, Agoff SN, Dahl KL, et al
    Cytologic persistence of malignant cells after transurethral resection of bladder tumors: Implications for concomitant manipulation of the urinary tract at the time of endoscopic resection.
    Cancer. 2017;125:114-119.
    Abstract    

    Abstract available

  105. KORPICS MC, Block AM, Martin B, Hentz C, et al
    Concurrent chemotherapy is associated with improved survival in elderly patients with bladder cancer undergoing radiotherapy.
    Cancer. 2017 Jun 5. doi: 10.1002/cncr.30719.
    Abstract    

    Abstract available

  106. ERIKSSON P, Sjodahl G, Liedberg F
    Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30455.
    Abstract    



  107. SEISEN T, Cole AP, Trinh QD
    Reply from Authors re: Girish S. Kulkarni, Zachary Klaassen. Trimodal Therapy is Inferior to Radical Cystectomy for Muscle-invasive Bladder Cancer using Population-level Data: Is There Evidence in the (Lack of) Details? Eur Urol. In press. http://doi.
    Eur Urol. 2017 May 29. pii: S0302-2838(17)30411.
    Abstract    



  108. D'ANDREA D, Shariat SF
    Re: Comparative Effectiveness of Treatment Strategies for Bladder Cancer with Clinical Evidence of Regional Lymph Node Involvement.
    Eur Urol. 2017 Jun 6. pii: S0302-2838(17)30481.
    Abstract    



  109. DYRSKJOT L, Reinert T, Algaba F, Christensen E, et al
    Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30475.
    Abstract    

    Abstract available

  110. PIETZAK EJ, Bagrodia A, Cha EK, Drill EN, et al
    Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
    Eur Urol. 2017 Jun 2. pii: S0302-2838(17)30466.
    Abstract    

    Abstract available

  111. POWLES T, Gomez de Liano A, Ackerman C
    Reply to Pontus Eriksson, Gottfrid Sjodahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First
    Eur Urol. 2017 Jun 9. pii: S0302-2838(17)30453.
    Abstract    



  112. GIACALONE NJ, Niemierko A, Shipley WU, Efstathiou JA, et al
    Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: A
    Eur Urol. 2017 Jun 19. pii: S0302-2838(17)30502.
    Abstract    



  113. BOSSCHIETER J, Vis AN, van der Poel HG, Moonen LM, et al
    Robot-assisted Laparoscopic Implantation of Brachytherapy Catheters in Bladder Cancer.
    Eur Urol. 2017 Jun 12. pii: S0302-2838(17)30494.
    Abstract    

    Abstract available

  114. HUSSAIN SA, Ansari J, Huddart R, Power DG, et al
    VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in t
    Int J Oncol. 2017;50:768-772.
    Abstract    

    Abstract available

  115. CHANG SS
    Re: Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.
    J Urol. 2017;198:40.
    Abstract    



  116. CHANG SS
    Re: EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-Specific and Overall Survival in Non-Muscle-Invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin.
    J Urol. 2017;198:39-41.
    Abstract    



  117. RADY M, Mostageer M, Rohde J, Zaghloul A, et al
    Therapy-relevant aberrant expression of MRP3 and BCRP mRNA in TCC-/SCC-bladder cancer tissue of untreated patients.
    Oncol Rep. 2017 Jun 2. doi: 10.3892/or.2017.5695.
    Abstract    

    Abstract available

  118. WANG H, Zhong J, Wu C, Liu Y, et al
    Stromal antigen 2 functions as a tumor suppressor in bladder cancer cells.
    Oncol Rep. 2017 Jun 12. doi: 10.3892/or.2017.5711.
    Abstract    

    Abstract available

  119. RIOUX-LECLERCQ N, Comperat E, Kammerer-Jacquet SF, Camparo P, et al
    [Pathological advances in renal, prostatic, bladder and testis neoplasia].
    Prog Urol. 2016 Jul 26. pii: S1166-7087(16)30070.
    Abstract    

    Abstract available

  120. POLETAJEW S, Zapala P, Radziszewski P
    Safety and Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
    Urol Int. 2017 Jun 10. doi: 10.1159/000477673.
    Abstract    

    Abstract available

  121. NAGAO K, Hara T, Nishijima J, Shimizu K, et al
    The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
    Urol Int. 2017 Jun 21. doi: 10.1159/000477912.
    Abstract    

    Abstract available

  122. DUNPHY KM, Garino MC, Shaw NM, Carvalho FL, et al
    When the Gold Standard Proves to be Fool's Gold - Blue Light Cystoscopy in a Case of High Risk Non-Muscle Invasive Bladder Cancer.
    Urology. 2017 May 31. pii: S0090-4295(17)30581.
    Abstract    



  123. SIHRA N, Diasuke N, Thurairaja R, Khan MS, et al
    Renal Tuberculosis Following Intravesical BCG for High-Grade Non-Muscle-Invasive Bladder Cancer.
    Urology. 2017 May 31. pii: S0090-4295(17)30587.
    Abstract    

    Abstract available

  124. PENG D, Gong YQ, Hao H, He ZS, et al
    Preoperative Prognostic Nutritional Index is a Significant Predictor of Survival with Bladder Cancer after Radical Cystectomy: a retrospective study.
    BMC Cancer. 2017;17:391.
    Abstract    

    Abstract available

  125. REULEN RC, de Vogel S, Zhong W, Zhong Z, et al
    Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer.
    PLoS One. 2017;12:e0178613.
    Abstract    

    Abstract available

  126. AFSHARI M, Janbabaei G, Bahrami MA, Moosazadeh M, et al
    Opium and bladder cancer: A systematic review and meta-analysis of the odds ratios for opium use and the risk of bladder cancer.
    PLoS One. 2017;12:e0178527.
    Abstract    

    Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design:


;